ES2248737T3 - Compuestos 1-(d-ciclopropilglicinil)-4-(piperidin-4-il)piperazina como inhibidores del factor xa de la serina proteasa. - Google Patents

Compuestos 1-(d-ciclopropilglicinil)-4-(piperidin-4-il)piperazina como inhibidores del factor xa de la serina proteasa.

Info

Publication number
ES2248737T3
ES2248737T3 ES03714138T ES03714138T ES2248737T3 ES 2248737 T3 ES2248737 T3 ES 2248737T3 ES 03714138 T ES03714138 T ES 03714138T ES 03714138 T ES03714138 T ES 03714138T ES 2248737 T3 ES2248737 T3 ES 2248737T3
Authority
ES
Spain
Prior art keywords
compound
formula
piperazine
compounds
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03714138T
Other languages
English (en)
Spanish (es)
Inventor
Michael Robert Wiley
Gary Lowell Engel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2248737T3 publication Critical patent/ES2248737T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES03714138T 2002-04-01 2003-03-24 Compuestos 1-(d-ciclopropilglicinil)-4-(piperidin-4-il)piperazina como inhibidores del factor xa de la serina proteasa. Expired - Lifetime ES2248737T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36852302P 2002-04-01 2002-04-01
US368523P 2002-04-01

Publications (1)

Publication Number Publication Date
ES2248737T3 true ES2248737T3 (es) 2006-03-16

Family

ID=28791889

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03714138T Expired - Lifetime ES2248737T3 (es) 2002-04-01 2003-03-24 Compuestos 1-(d-ciclopropilglicinil)-4-(piperidin-4-il)piperazina como inhibidores del factor xa de la serina proteasa.

Country Status (24)

Country Link
US (1) US7166606B2 (cg-RX-API-DMAC7.html)
EP (1) EP1492767B1 (cg-RX-API-DMAC7.html)
JP (1) JP2005531529A (cg-RX-API-DMAC7.html)
KR (1) KR20040094892A (cg-RX-API-DMAC7.html)
CN (1) CN1288135C (cg-RX-API-DMAC7.html)
AT (1) ATE303990T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003218147A1 (cg-RX-API-DMAC7.html)
BR (1) BR0308870A (cg-RX-API-DMAC7.html)
CA (1) CA2478340A1 (cg-RX-API-DMAC7.html)
CR (1) CR7497A (cg-RX-API-DMAC7.html)
DE (1) DE60301569T2 (cg-RX-API-DMAC7.html)
DK (1) DK1492767T3 (cg-RX-API-DMAC7.html)
EA (1) EA007300B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP045329A (cg-RX-API-DMAC7.html)
ES (1) ES2248737T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20040900B1 (cg-RX-API-DMAC7.html)
IL (1) IL164018A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04009640A (cg-RX-API-DMAC7.html)
NO (1) NO20044688L (cg-RX-API-DMAC7.html)
NZ (1) NZ535402A (cg-RX-API-DMAC7.html)
PL (1) PL373066A1 (cg-RX-API-DMAC7.html)
UA (1) UA76849C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003084929A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200407418B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6834308B1 (en) 2000-02-17 2004-12-21 Audible Magic Corporation Method and apparatus for identifying media content presented on a media playing device
US7363278B2 (en) 2001-04-05 2008-04-22 Audible Magic Corporation Copyright detection and protection system and method
US8972481B2 (en) 2001-07-20 2015-03-03 Audible Magic, Inc. Playlist generation method and apparatus
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
WO2018093716A1 (en) * 2016-11-18 2018-05-24 Merck Sharp & Dohme Corp. FACTOR XIIa INHIBITORS
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011658A1 (en) 1997-08-29 1999-03-11 Proteus Molecular Design Ltd. Meta-benzamidine derivatives as serin protease inhibitors
CA2375920A1 (en) 1999-06-14 2000-12-21 Eli Lilly And Company Compounds
CA2383008A1 (en) 1999-06-14 2000-12-21 Amanda Jane Lyons Compounds
GB0030305D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030304D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030306D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030303D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
TWI257389B (en) 2001-06-12 2006-07-01 Lilly Co Eli Pharmaceutical compound
US7265121B2 (en) * 2001-07-26 2007-09-04 Eli Lilly And Company Chemical compounds

Also Published As

Publication number Publication date
CA2478340A1 (en) 2003-10-16
UA76849C2 (uk) 2006-09-15
HRP20040900B1 (en) 2006-02-28
WO2003084929A1 (en) 2003-10-16
EA007300B1 (ru) 2006-08-25
BR0308870A (pt) 2005-01-04
PL373066A1 (en) 2005-08-08
DE60301569D1 (de) 2005-10-13
KR20040094892A (ko) 2004-11-10
EA200401290A1 (ru) 2005-02-24
ZA200407418B (en) 2005-09-15
DK1492767T3 (da) 2005-11-28
EP1492767A1 (en) 2005-01-05
US7166606B2 (en) 2007-01-23
HK1070363A1 (en) 2005-06-17
CR7497A (es) 2005-01-17
JP2005531529A (ja) 2005-10-20
HRP20040900A2 (en) 2004-12-31
WO2003084929A8 (en) 2004-05-21
NZ535402A (en) 2006-02-24
ATE303990T1 (de) 2005-09-15
AU2003218147A1 (en) 2003-10-20
MXPA04009640A (es) 2005-01-11
NO20044688L (no) 2004-10-29
ECSP045329A (es) 2004-11-26
CN1288135C (zh) 2006-12-06
DE60301569T2 (de) 2006-06-14
IL164018A0 (en) 2005-12-18
EP1492767B1 (en) 2005-09-07
US20050096328A1 (en) 2005-05-05
CN1642914A (zh) 2005-07-20

Similar Documents

Publication Publication Date Title
US10882855B2 (en) Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases
US20070155790A1 (en) Meta-benzamidine derivatives as serine protease inhibitors
EP0769498B1 (en) Sulfonamide derivatives with elastase inhibiting activity
ES2330461T3 (es) Diamidas antitromboticas.
BG64276B1 (bg) Карбок'амидни производни на пип...ридина за л...-...ни... на 'ромбозни заболявания
EP1492767B1 (en) Certain 1-(d-cyclopropylglycinyl)-4-(piperidin-4-yl)piperazine compounds as inhibitors of the serine protease factor xa
US7427632B2 (en) Factor Xa inhibitors
ES2298386T3 (es) 1-glicinil-4-(1-metilpiperidin-4-il)piperazinas y -piperidinas como antagonistas del factor xa.
US7115609B2 (en) Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases
ES2242086T3 (es) Ciertos derivados de glicina como inhibidores del factor xa para el tratamiento de trastornos tromboticos.
HK1070363B (en) Certain 1-(d-cyclopropylglycinyl)-4-(piperidin-4-yl)piperazine compounds as inhibitors of the serine protease factor xa